XML 38 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Schedule of Financial Instruments Measured at Fair Value As of December 31, 2024, the Company's financial instrument measured at fair value in the accompanying Condensed Consolidated Balance Sheet on a recurring basis was the following:
As of
December 31, 2024
(In thousands)Level 1Level 2Level 3Total
Liabilities
Contingent consideration liability (1)
$— $1,191 $— $1,191 
(1) The contingent consideration was recognized as part of the 2021 Shareablee acquisition. In April 2022, the contingency was resolved and the full amount was deemed payable. In December 2024, the Company elected to settle the third and final installment in cash, which was paid in the first quarter of 2025. The fair value of this liability as of December 31, 2024 was equal to the payment due. The contingent consideration liability was classified within other current liabilities in the Condensed Consolidated Balance Sheet as of December 31, 2024.
Schedule of Changes in Level 3 Fair Valued Instruments
The following table presents the changes in the Company's recurring Level 3 fair valued instruments for the nine months ended September 30, 2024:
(In thousands)Warrants Liability
Balance as of December 31, 2023$669 
Total gain recognized due to remeasurement and expiration of warrants (1)
(669)
Balance as of September 30, 2024$— 
(1) The gain due to remeasurement and expiration of warrants was recorded in other income, net, in the Condensed Consolidated Statement of Operations and Comprehensive Income (Loss). The Series A Warrants expired unexercised on June 26, 2024.